InMed has seen a strong upward trend over the past few weeks, going from a close of $.27 at the end of August to $.50 currently on the back of strong announcements.
In the past few weeks they have had some major news:
- They filed a provisional patent for their proprietary biosynthesis program which could change the industry and unlock a $6 Billion industry.
- They announced the addition of Ben Paterson from Eli Lilly as a consultant. Mr. Paterson helped scale Eli lilly to a multi billion dollar company after they unlocked a breakthrough in biosynthesis manufacturing, much the same way as InMed has.
- They were added to the CSE25 Index, as one of the twenty five largest companies on the CSE Composite Index.
Analysts are taking notice of this strong upward trajectory and keeping an eye out for InMed.
From the Hayden Business Journal:
Monitoring the numbers for Inmed Pharmaceuticals Inc (IMLFF), we have recorded that the Percentage Price Oscillator is currently higher than the signal line. With the PPO indicator above the line, traders may be looking for a possible bullish move.
InMed has had a strong few weeks, and it is definitely starting to show.
Read the full story here